Favorable Tolerability Profile Demonstrated in 1-year Safety Study FREMONT, Calif. , Jan. 3, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program, designed to support the registration of
Ardelyx to Receive Up to $125 Million in Upfront Payment and Subsequent Milestones FREMONT, Calif. , Dec. 11, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company
Ardelyx to Receive a $30 Million Upfront Payment and Subsequent Milestones FREMONT, Calif. and TOKYO , Nov. 28, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) and Kyowa Hakko Kirin Co., Ltd. ( Tokyo : 4151, " Kyowa Hakko Kirin "), today announced that they have entered into a license agreement
Company to Host Conference Call at 8:30 a.m. ET Today FREMONT, Calif. , Nov. 21, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today provided an update on the development of its cardiorenal pipeline. The company's second registration study for tenapanor for the treatment of hyperphosphatemia
FREMONT, Calif. , Nov. 7, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today provided an update on its clinical programs and reported financial results for the third quarter ended September 30, 2017 . "2017 has been a landmark year for Ardelyx , with three statistically significant Phase 3
Preclinical data provide new mechanistic insights linking tenapanor's analgesic action to a well-established pain pathway for the treatment of patients with IBS-C FREMONT, Calif. , Oct. 16, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today reported that data from preclinical studies have
Six of 12-week combined responder rate shows clear benefit in treated patients with consistent response throughout 26 weeks Best-in-class, nine of 12-week combined responder rate demonstrates ability to normalize patients' bowel function Conference call to be held today at 4:30 p.m.
Restructuring Aligns Resources on Execution of Late-Stage Program MilestonesT3MPO-2 Phase 3 Trial Results of Tenapanor for IBS-C on Track for Early Fourth Quarter; RDX7675 Onset-of-Action Data Planned for Fourth QuarterConference Call to be Held at 8:00 a.m. ET Today
FREMONT, Calif. , Aug. 2, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today announced that management will host a conference call in conjunction with its second